Long-term intravenous hydroxyurea infusi
โ
Martin S. Blumenreich; Michael J. Kellihan; U. Geetha Joseph; Kim A. Lalley; Eli
๐
Article
๐
1993
๐
John Wiley and Sons
๐
English
โ 384 KB
๐ 1 views
Background. Hydroxyurea is an S-phase specific drug. Constant exposure of tumor cells with a low Sphase fraction to the agent may result in improved cell kill. Because of its short half-life, a continuous intravenous infusion may result in better tumor exposure than intake by mouth. The goal of this